Immuneel Therapeutics has entered into a partnership with healthcare crowdfunding platform Impact Guru and healthcare-focused lending marketplace CarePal Money to improve financial access to CAR T-cell therapy in India.
The collaboration aims to address affordability, one of the biggest barriers to advanced cancer treatment in the country. CAR T-cell therapy, a highly personalised treatment for certain blood cancers, has shown promising results for patients with relapsed or refractory disease but remains out of reach for many due to high upfront costs and limited financing options.
Through this integrated access model, Immuneel seeks to bridge the gap between medical innovation and patient affordability by combining digital crowdfunding with structured healthcare lending.
As part of the partnership, Impact Guru will support patients and families in raising funds through its online crowdfunding platform, enabling community-driven donation campaigns and awareness initiatives. The platform is backed by a donor network of over 50 lakh contributors. CarePal Money will provide access to tailored medical loans by connecting eligible patients with its network of NBFC partners, offering structured credit solutions to help manage treatment-related expenses.
Immuneel Therapeutics will continue to deliver globally benchmarked CAR T-cell therapies in India and will work closely with both partners to align financial support with clinical timelines and patient needs.
The collaboration is expected to function as a scalable access model for emerging markets, where advances in cell and gene therapies require sustainable financing solutions. By integrating clinical innovation with crowdfunding and healthcare lending, the partners aim to complement existing public health systems, insurance coverage, and future reimbursement pathways for CAR T-cell therapy in India.